Can I Take Quercetin with Spironolactone?

What Quercetin Is and Why People Combine It with Spironolactone

Quercetin is a flavonoid found in onions, apples, capers, and red wine, and it is sold as a dietary supplement in doses that commonly range from 250 mg to 1,000 mg per day. It is marketed for anti-inflammatory, antihistamine, and antioxidant effects. People taking spironolactone for hormonal acne sometimes add quercetin for allergy support or general anti-inflammatory purposes, or because they have seen it described as having anti-androgenic properties similar in spirit to spironolactone's.

Laboratory research has looked at quercetin's effects on inflammatory signaling in skin cells, including mast-cell mediators and cytokine production, and some cell-culture work has explored effects on sebaceous gland activity. These are preclinical findings from cell or animal models. They describe biological plausibility, not proof that oral quercetin supplementation changes acne outcomes in people, and no randomized controlled trial has established that oral quercetin reduces acne in humans.

Spironolactone's use for hormonal acne is better established. It is prescribed off-label in adult women, typically at 50 to 150 mg daily, and has supporting evidence from systematic reviews and controlled trials in dermatology literature [1]. The exact effect size, trial design, and patient population behind any specific number should be confirmed against the primary paper before it is quoted to a reader, since acne trial designs vary widely in dose, duration, and outcome measures.

How Spironolactone Is Metabolized and Why CYP3A4 Matters

Spironolactone is a prodrug. After oral ingestion it undergoes extensive first-pass hepatic metabolism, primarily through CYP3A4, with additional involvement of CYP2C8, to form active metabolites including canrenone and 7-alpha-thiomethylspironolactone. These metabolites are responsible for most of spironolactone's aldosterone-antagonist and anti-androgenic activity. This metabolic pathway is well established pharmacology and is reflected in spironolactone's FDA prescribing information [2].

A compound that inhibits CYP3A4 can slow the conversion of spironolactone to its metabolites and can also slow clearance of those metabolites, which generally raises total drug exposure. Quercetin has shown CYP3A4-inhibiting activity in laboratory (in vitro) enzyme assays and in some animal studies. Whether that translates into a clinically meaningful increase in spironolactone or canrenone levels in people taking oral quercetin supplements has not been directly studied. Some published pharmacokinetic work in humans has examined quercetin's effect on other CYP3A4 substrate drugs, and some of it points to a modest, detectable effect on drug exposure. The magnitude reported varies by study design and quercetin formulation, and applying a number from a different substrate drug to spironolactone specifically is an extrapolation, not a measurement. A pharmacist reviewing this combination should treat any specific percentage as an estimate pending the primary literature, not as an established figure.

Quercetin's inhibition of CYP3A4, where it has been measured, is generally described as moderate rather than strong. Strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, can raise a sensitive substrate's exposure several-fold. Quercetin's effect, based on the available in vitro and limited human data, appears to be smaller than that, though the exact size in the context of spironolactone specifically is unverified.

Pharmacodynamic Overlap: Potassium and Blood Pressure

Independent of any metabolic interaction, quercetin and spironolactone share two areas of biological effect that could compound each other.

Potassium

Spironolactone blocks mineralocorticoid receptors in the distal nephron, which reduces aldosterone-driven potassium excretion. This is the mechanism behind its well-documented, dose-dependent hyperkalemia risk, and it is the reason spironolactone prescribing already requires periodic potassium checks, particularly at higher doses or with concurrent use of ACE inhibitors, ARBs, or NSAIDs [2].

Whether quercetin, taken on its own, meaningfully raises serum potassium in healthy adults is not well established from the sources reviewed here. Some clinical trials of quercetin have measured blood pressure and vascular biomarkers as their primary focus rather than potassium, so a precise potassium figure attributed to quercetin alone should be verified against a study designed to measure that outcome specifically before it is presented as fact. The more defensible statement is that spironolactone's potassium-raising effect is well documented, and stacking any additional potassium-affecting substance on top of it, including quercetin, is a reasonable general precaution rather than a precisely quantified additive risk.

Blood Pressure

Spironolactone lowers blood pressure through aldosterone blockade and natriuresis. Separately, at least one randomized trial has reported that quercetin supplementation (around 730 mg per day) reduced systolic blood pressure in adults with hypertension over several weeks [3]. If that effect holds in a person also taking spironolactone, mainly for acne rather than hypertension, the combination could plausibly increase the chance of symptomatic low blood pressure, lightheadedness, or dizziness on standing, particularly in someone who starts with normal or low-normal blood pressure. This is a reasonable inference from two separately studied effects, not a finding from a trial that combined the two agents.

Does Quercetin Have Androgen-Related Activity That Could Overlap with Spironolactone?

Spironolactone blocks androgen receptors and reduces testosterone production, and this is central to why it helps hormonal acne. Some flavonoids have shown androgen-receptor-related activity in laboratory cell-line studies. Whether quercetin specifically produces a clinically meaningful anti-androgen effect in people at typical supplement doses has not been established by human clinical trial data, and claims that attach a precise binding number to quercetin in this context should be checked directly against the source paper, since flavonoid classes and specific compounds are easy to conflate in secondary summaries. Until better data exist, any additive hormonal effect from combining quercetin with spironolactone should be treated as a theoretical possibility worth documenting, not a quantified risk.

Quercetin and P-glycoprotein: A Secondary Absorption Pathway

Spironolactone is a substrate of P-glycoprotein (P-gp), a transporter that limits drug absorption in the gut. Quercetin has inhibited P-gp in laboratory and animal studies, including at least one rat study showing increased oral bioavailability of a P-gp substrate drug when co-administered with quercetin [4]. If a similar effect occurs with spironolactone in humans, it would add to, rather than replace, any CYP3A4-mediated increase in exposure. This mechanism has not been directly studied for the spironolactone-quercetin pair and is inferred from P-gp interaction data on other drugs.

Evidence-Status Interaction Assessment

The table below distinguishes between research directly examining spironolactone with supplements from theoretical interactions based on how these substances work in the body, and identifies gaps requiring further study. Reference it when discussing this combination with your doctor or pharmacist, but not in place of that conversation.

What Clinical Interaction References Generally Say

Drug-supplement interaction references maintained by pharmacists (Natural Medicines-type databases, Lexicomp-style modules used at academic centers) commonly flag flavonoid CYP3A4 inhibitors like quercetin as worth monitoring alongside CYP3A4-metabolized drugs, generally at a "monitor" rather than "avoid" level, when the interaction is pharmacokinetic and moderate. Exact wording and rating levels change as these databases are updated, and this article does not reproduce specific database language here because it cannot be verified as current. A pharmacist with active access to one of these tools can confirm the live rating for this specific pairing.

Heart failure prescribing guidance for spironolactone, where the drug is used at similar or higher doses than for acne, generally recommends caution when combining potassium-sparing agents with anything that raises potassium or slows spironolactone clearance, along with routine potassium monitoring [5]. That general principle is well supported; the exact wording of any specific guideline statement should be checked against the primary document before being quoted directly, since guideline language changes between revisions.

Questions to Bring to Your Prescriber or Pharmacist

This is not a substitute for individualized advice, and it is not a dosing protocol. It is a starting list for a conversation.

• I am taking (or considering) quercetin at this dose and this formulation (standard, piperine-enhanced, or phytosome). Does that change how you monitor my spironolactone?
• Should we check a baseline potassium level before I start quercetin, and when should I recheck it?
• At my current spironolactone dose, does adding quercetin change your recommendation?
• Do I have any other risk factors, reduced kidney function, an ACE inhibitor or ARB, an NSAID, that would make this combination riskier for me specifically?
• Are there lower-interaction alternatives that would meet my reason for taking quercetin (allergy support, general anti-inflammatory use)?

A pharmacist or prescriber, not a general health article, is the right source for a specific go/no-go decision and for any dosing or timing instructions, because that decision depends on your dose, kidney function, other medications, and lab values.

Special Populations Where Caution Is More Clearly Warranted

Reduced Kidney Function

Spironolactone's active metabolites are cleared renally, and spironolactone is generally avoided or used with extra caution when glomerular filtration rate is significantly reduced, because of hyperkalemia risk. Anything that adds to potassium retention or slows clearance narrows that safety margin further. People with chronic kidney disease should not add quercetin to a spironolactone regimen without input from their kidney or prescribing clinician.

Concurrent ACE Inhibitors or ARBs

ACE inhibitors (such as lisinopril or enalapril) and angiotensin receptor blockers (such as losartan or valsartan) already raise potassium by reducing aldosterone secretion. Adding spironolactone on top of one of these drugs is already a monitored combination in routine practice. Adding quercetin as a third potassium-relevant variable is a reasonable thing to flag explicitly to the prescriber rather than assume is fine because each individual pair is common.

High-Bioavailability Quercetin Formulations

Standard quercetin supplements have low oral bioavailability, commonly cited in the low single-digit percentages. Formulations that add piperine (black pepper extract) or use phytosome/lecithin-based delivery are designed to increase absorption substantially. At least one pharmacokinetic study comparing quercetin phytosome to standard quercetin aglycone at the same nominal dose found several-fold higher blood levels with the phytosome form [6]. If a patient is using an enhanced-bioavailability product, any mechanism-based concern about CYP3A4 or P-gp inhibition should be treated as potentially larger than the standard-dose data would suggest, since the actual quercetin exposure is higher even though the label dose looks the same.